Johnson & Johnson recently announced updated findings from the Phase 3 MARIPOSA study. The study evaluated the efficacy of Rybrevant (amivantamab-vmjw) in combination with Lazertinib as a first-line treatment for patients with EGFR-mutated NSCLC.
The results indicate that this combination therapy substantially reduces the emergence of resistance driven by EGFR and MET mutations, in contrast to osimertinib treatment. This reduction in resistance is a significant development.
These findings expand upon earlier data showing superior overall survival with the Rybrevant and Lazertinib combination. The projected overall survival exceeds four years, a considerable improvement compared to the median survival observed with osimertinib.
Resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, is a critical obstacle to long-term disease control. This highlights the need for innovative approaches to prevent resistance and improve patient outcomes.
Professor Sanjay Popat, a medical oncologist at the Royal Marsden Hospital and the Institute of Cancer Research in the United Kingdom, commented on the significance of these results. He noted that the combination therapy represents a major advancement in first-line treatment for EGFR-mutated lung cancer.
The updated MARIPOSA analysis confirmed that patients receiving Rybrevant plus Lazertinib had a lower incidence of both MET amplification and secondary EGFR mutations. MET amplifications were observed in a significantly smaller percentage of patients in the combination group compared to the osimertinib group. Similarly, the rate of secondary EGFR mutations was notably lower in the combination group.
Joshua Bauml, Vice President and Lung Cancer Disease Area Leader at Johnson & Johnson Innovative Medicine, emphasized the importance of first-line treatment decisions in EGFR-mutated NSCLC. He stated that the combination therapy alters the disease’s biology by inhibiting resistance pathways, leading to extended survival and preserving future treatment options.
The safety profile of the Rybrevant and Lazertinib combination remained consistent with previous findings. Most adverse events of grade 3 or higher occurred early in treatment. Prophylactic measures can help mitigate the severity of certain side effects.
Rybrevant plus Lazertinib is currently approved in the United States, Europe, and other global markets for first-line treatment of EGFR-mutated NSCLC. The MARIPOSA study, a randomized Phase 3 trial, enrolled over 1,000 patients. The study’s primary endpoint was progression-free survival, assessed using RECIST v1.1 guidelines.
Rybrevant (amivantamab-vmjw) is a fully human bispecific antibody targeting EGFR and MET. Lazertinib is an oral, third-generation, brain-penetrant EGFR TKI. The National Comprehensive Cancer Network (NCCN) guidelines recommend this combination as first-line therapy for patients with specific EGFR mutations. Both drugs are undergoing further investigation in various clinical trials.
Related
